Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin

Size: px
Start display at page:

Download "Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin"

Transcription

1 Roche Positioning AVASTIN-based therapy as essential to treat cancer Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected. 2 1

2 Introduction Update on Summary 3 Differentiated and rejuvenated product portfolio From 1 to 9 products with sales around or above CHF 1 billion Pharmaceuticals key products (CHF billion) By year of market introduction 0 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 Boniva Tarceva Pegasys Herceptin Xeloda NeoRecormon/ Epogin MabThera/ Rituxan CellCept Rocephin Roaccutane 4 2

3 Our oncology strategy: Move the standards of care New tumor types, new combinations, new lines of intervention Clinically differentiated product Example target all tumor types target all important combinations target earlier (adjuvant) intervention Superior outcome for patients 3 rd line 3 rd line 2 nd line 3 rd line 2 nd line 1 st line 2 nd line 1 st line Adjuvant 1 st line Adjuvant Adjuvant NSCLC CRC NHL Ovarian Gastric Prostate RCC BC Completed Ongoing In preparation 5 Introduction Update on Summary 6 3

4 Roche Oncology: Strongest growing franchise : Best growing oncology brand ever CHF billion vs local growth +20 % 6 % +11 % 44 % +14 % Sales launch compared to other cancer therapies (US plus top-5 EU markets 1 ) 5 50 % +28 % Europe/RoW US Japan Quarters since launch 1 Source: IMS. Products included are, Alimta, Arimidex, Camptosar, Eloxatine, Erbitux, Femara, Gemzar, Herceptin, MabThera, Nexavar, Sutent, Tarceva, Taxol, Taxotere, Xeloda 7 Backbone of cancer therapy Number of incident cases per year* 450' ' ' ' ' ' ' '000 50'000 0 *in USA plus top 5 EU countries Breast Prostate Lung Colon and rectum Bladder Non-Hodgkin lymphoma s features remain unique Major cancers tested with VEGF inhibition is broadly applicable in cancer therapy Exclusively targeting VEGF (in contrast to non-specific anti-vegf-r TKIs) Overall good tolerability Preferred partner for combinations Melanoma Stomach Uterus Kidney Leukaemia Pancreas Oral cavity Ovary Liver Brain, nervous system Oesophagus Multiple myeloma Larynx Thyroid Cervix Other pharynx Testis Hodgkin lymphoma Nasopharynx 8 4

5 still early in its journey Realising full potential across tumour types Tumour Colon/ rectal Lung (NSCLC) Breast (HER2-) Breast (HER2+) Kidney (RCC) Early/adjuvant (Potential for cure) (AVANT, NSABP C-08, E5202, E5204) (E1505) (BEATRICE, E5103) (BETH w/herceptin) also trialed in gastric, ovarian, prostate, anhl, and brain (GBM) (Trial names) [Approval status]. More trials are ongoing than listed above. Advanced/metastatic (Extending life) 1 st -line of treatment 2 nd -line of treatment Launched [EU, US, JP; broad label in 1st and subsequent lines] Launched [EU majority of chemos, US carboplatin/paclitaxel] Launched [EU paclitaxel] (AVADO, RIBBON-1) (AVEREL w/herceptin) Launched [EU; with interferon] (BETA Lung w/tarceva) (RIBBON-2, incl. w/xeloda) 9 Major growth opportunities outside the US Herceptin leading the way 100 Herceptin Xeloda Tarceva MabThera/ Rituxan 80 % of Total 2007 Sales % 62 % 53 % 48 % % 0 EU / ROW (incl. Japan) US 10 5

6 in 1 st line mcrc Largest improvement in overall survival in phase III Median survival (months) IFL + placebo: 15.6 vs IFL + : 20.3 HR = 0.66 (95% CI: ) p< OS estimate IFL + IFL + placebo Months CI = confidence interval; IFL irinotecan, bolus 5-FU/FA H. Hurwitz, et al. NEJM 2004;350: in 1 st -line mcrc Consistently delivers the best PFS outcome Hurwitz Hurwitz Douillard BEAT BRiTE AVIRI CRYSTAL NO16966 NO16966 PACCE OPUS IFL n=411 IFL+ n=402 FOLFIRI n=109 FOLFIRI + n=503 FOLFIRI + n=280 FOLFIRI + n=209 FOLFIRI + Cetuximab n=608 FOLFOX/XELOX n=701 FOLFOX/XELOX + n=699 FOLFOX + n=400 FOLFOX + Cetuximab n= months : The only biologic agent with OS benefit in 1 st -line mcrc Adds benefit to all chemotherapies 12 6

7 BRiTE: post 1st progression therapy beyond progression: potential to increase survival No post PD treatment n=253 No post PD n=531 post PD n= Months Superior survival in patients continuing beyond progression demonstrated in a multivariate analysis (HR=0.53, p < 0.001) A. Grothey et al. ASCO Expanding the market for and Xeloda in mcrc to be combined with any chemo in any line of treatment Current EU label: 5-FU or 5-FU + Irinotecan Xeloda 14% 5-FU 8% Oxaliplatin 53% Irinotecan 25% Xeloda Xeloda 14% 5-FU 8% Oxaliplatin 53% Irinotecan 25% New EU label: Any fluoropyrimidine combination Full label any combo 100% Full label any combo 100% New EU label: Any combo, including with Source: Synovate Healthcare

8 in mcrc Conclusions Four randomized trials show compelling efficacy AVF2107g E3200 AVF2192 NO16966 Aiming for cure High rates of surgeries with curative intent shown in BEAT and NO16966 Resection rates for liver mets only patients in NO16966: 19.2% in arm (vs 12.9%) Secondary resection as a concept is promising, but requires further investigation Incidence: 155,000 cases 1, 2) 1) US and top 5 EU, 2) stage IV 15 in adjuvant colon cancer Key phase III trials fully recruited Treatment regimen Number of patients Recruitment duration Efficacy analysis 2,700 NSABP C-08 FOLFOX-6 ± Q until Q First interim look: Q Subsequently every 6 months Next interim look: Q AVANT FOLFOX-4 ± XELOX + 3,450 Q until Q Event-driven analysis Filing 2010 (or earlier) 2010 (or earlier) 1) US and top 5 EU; 2) stage II high risk, and stage III Incidence: 150,000 cases 1,2) 16 8

9 in 1 st line NSCLC (E4599) First drug in a decade to show an overall survival benefit PC + PC 12 mo. 24 mo. 51% 23% 44% 15% HR=0.79 (0.67, 0.92); p = OS estimate Months A. Sandler, et al. NEJM 2006 PC= paclitaxel/carboplatin 17 launching with best-possible label in 1 st -line NSCLC market in Europe 1 Monotherapy / Others 33% Platinum + Vinorelbine 15% Platinum + Gemcitabine 36% Platinum + Taxane 16% Monotherapy / Others 33% label: Platinumbased chemo 67% in combo with all current standards (platinum) Source: Synovate Healthcare, MAT Q3 2007; 1 in non squamous NSCLC 18 9

10 in 1st line NSCLC Conclusions First front-line treatment to demonstrate extended survival in over a decade Efficacy demonstrated in two randomized phase III trials (E4599 and AVAiL) Generally well tolerated Approved in US and approved in EU with a broad label in combination with any platinum-based chemotherapy regimens at least 50% of NSCLC population covered Incidence: 275,000 cases 1, 2) 1) US and top 5 EU, 2) stage IIIb and IV 19 in adjuvant lung cancer High unmet medical need E1505 Stage IB to IIIA adjuvant squamous and non-squamous NSCLC 1500 patients Started Q Chemotherapy +/- (15 mg/kg q3 weeks) Limited therapeutic options currently available Incidence: 135,000 cases 1) 1) US and top 5 EU 20 10

11 Establishing in metastatic breast cancer Strong commitment Current EU label: with paclitaxel Future broad target label Xeloda 17% other 19% Taxane 23% other 19% (e.g. monotherapy Vinorelbine) Anthracycline 25% Anthracyc./ Taxane 16% target label 81% US submission for 1 st line mbc ODAC split vote Dec 5, 2007 FDA action date Feb 23, 2008 Further phase III studies im mbc to report in 2008 AVADO (docetaxel +/- ): primary objective met Feb 2008 RIBBON-1 (var. chemos +/- ): data expected in H Incidence: 100,000 cases 1, 2) Source: Genactis MBC study Q ) US and top 5 EU, 2) stage IV, HER2-pos. and neg. 21 in adjuvant breast cancer Large opportunity major phase III trials started Phase II E2104 E 5103 BEATRICE BETH Patient population HER2-negative HER2-negative HER2-, ER-, PRnegative HER2-positive Number of patients ~3600 Design Primary endpoint Anthracylines + followed by paclitaxel + ( 2 arms) safety AC +/- followed by paclitaxel +/- (3 arms) Disease-free survival Antracycline or taxane-based chemos +/- Disease-free survival Chemo + Herceptin +/- Disease-free survival Status Initial safety results presented at SABCS 2007 FPI Q FPI Q Expect FPI H ) US and top 5 EU Incidence: 320,000 cases 1) 22 11

12 Introduction Update on Summary 23 Roche key therapeutic areas Entering new therapeutic areas beyond oncology Oncology Xeloda MabThera Herceptin Tarceva Pertuzumab R1507 (IGF-1R mab) Apomab Apo2L/TRAIL 14 phase I compounds On Hand RA/Autoimmune MabThera Actemra R1594 ocrelizumab PNP inhibitor 7 phase I compounds Metabolic R1583 GLP-1 R1658 CETP Inh. R1439 dual PPAR R1579 DPP-IV 6 phase I compounds Promising Late Stage Virology Tamiflu Pegasys R3484 HPV16 R1626 HCV pol. Inh. R7128 HCV pol. Inh. R7227 HCV prot. inh. Emerging Mid-Term CNS 4 phase I compounds Early Stage 24 12

13 Roche: A unique investment case Clear and focused strategy Medically-differentiated products; poised to become leader in Personalized Healthcare Attractive risk profile Low generic risk; lowest among European large-cap players 42 phase III projects; many additional indications Assets in place for sustained success World market leader in Oncology Emerging Rheumatology & Autoimmune franchises Promising phase II pipeline in Diabetes, Metabolism; early-stage compounds in CNS and Virology Industry-leading organic growth & value creation 2007: Sales +10 %, Core EPS +20% Unique high-tech healthcare investment 25 Our objectives for 2008 Sales High single-digit local currency sales increase for Roche Group (excl. Tamiflu pandemic 1 ) Above-market sales growth 1 in both divisions Core EPS Core earnings per share target 2 at least at record 2007 level despite significant increase in R&D investment and considerably lower Tamiflu pandemic sales Shareholder return Continuous increase in dividend pay-out ratio over the next 3 years 1 Excluding government and corporate stockpiling orders of Tamiflu for pandemic use 2 At constant exchange rates Barring unforeseen events 26 13

14 r 14

Kapil Dhingra, VP,Head Oncology DBA

Kapil Dhingra, VP,Head Oncology DBA Lehman Global Healthcare Conference 18 March 2008, Miami Kapil Dhingra, VP,Head Oncology DBA Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking

More information

Roche: Committed to Innovation. William M. Burns, CEO Roche Pharmaceuticals

Roche: Committed to Innovation. William M. Burns, CEO Roche Pharmaceuticals Roche: Committed to Iovation William M. Burns, CEO Roche Pharmaceuticals This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

Roche: Building on strength

Roche: Building on strength Roche: Building on strength Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO 1 This presentation contains certain forward-looking statements. These forward-looking statements may

More information

Clinical Development at Roche: Driving the paradigm shift

Clinical Development at Roche: Driving the paradigm shift Clinical Development at Roche: Driving the paradigm shift Jean-Jacques Garaud, MD Global Head Pharma Development, Chief Medical Officer Roche UBS Global Life Science Conference, New York, September 22,

More information

Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010

Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010 Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking statements may

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

Roche A sustainable business model based on innovation and productivity gains. Karl Mahler, Head of Investor Relations

Roche A sustainable business model based on innovation and productivity gains. Karl Mahler, Head of Investor Relations Roche A sustainable business model based on innovation and productivity gains Karl Mahler, Head of Investor Relations 1 This presentation contains certain forward-looking statements. These forward-looking

More information

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain

More information

Science, patient benefits and productivity

Science, patient benefits and productivity Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011 Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Pascal Soriot, Head of Strategic Marketing

Pascal Soriot, Head of Strategic Marketing Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage

More information

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Roche. Pascal Soriot COO Roche Pharmaceuticals

Roche. Pascal Soriot COO Roche Pharmaceuticals 1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015 Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words

More information

Focus and value creation

Focus and value creation Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking

More information

Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012

Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Roche: Defining priorities for a high tech healthcare company

Roche: Defining priorities for a high tech healthcare company Roche: Defining priorities for a high tech healthcare company Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO October 2007 1 This presentation contains certain forward-looking

More information

Roche: defining priorities for a high tech healthcare company

Roche: defining priorities for a high tech healthcare company Roche: defining priorities for a high tech healthcare company Erich Hunziker, CFO and Deputy Head of the Corporate Executive Committee June 2007 1 This presentation contains certain forward-looking statements.

More information

Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013

Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013 Oncology Treatment Trends and Implications for Future Drug Development In China Presented by Stephanie Hawthorne 16 April 2013 Economic development, demographic shift, regulatory environment change, industry

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

UBS European Conference 2013

UBS European Conference 2013 UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

ESMO IO Congress 2017, Geneva. Roche Analyst Call. Thursday, 7 December 2017

ESMO IO Congress 2017, Geneva. Roche Analyst Call. Thursday, 7 December 2017 ESMO IO Congress 2017, Geneva Roche Analyst Call Thursday, 7 December 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

Media Release. Basel, 26 March 2018

Media Release. Basel, 26 March 2018 Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live

More information

Roche First quarter Roche First Quarter 2007 Apr. 18,

Roche First quarter Roche First Quarter 2007 Apr. 18, r Roche First quarter 2007 April 18, 2007 Apr. 18, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,

More information

Helvea Swiss Equities Conference, January 15, 2010

Helvea Swiss Equities Conference, January 15, 2010 Translating excellence in science into customer benefit Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Global Product Strategy - Avastin Franchise Leader Helvea Swiss Equities Conference,

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Genta Incorporated. A Multiproduct Late-Stage Oncology Company

Genta Incorporated. A Multiproduct Late-Stage Oncology Company Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking

More information

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Roche: Committed to Innovation

Roche: Committed to Innovation Roche: Committed to Innovation William M. Burns CEO Roche Pharmaceuticals UBS Swiss Equity Conference, Zurich, 26. November 2009 This presentation contains certain forward-looking statements. These forward-looking

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and

More information

Roche YTD September 2007 October 16, 2007

Roche YTD September 2007 October 16, 2007 Roche YTD September 2007 October 16, 2007 October 16, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,

More information

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011 Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived

More information

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening

More information

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12,

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12, Investor Update Basel, 26 April 2018 Roche reports a strong start in 2018 Group sales increase 6% 1 at constant exchange rates and 5% in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly

More information

Investor Update. Basel, 10 May 2018

Investor Update. Basel, 10 May 2018 Investor Update Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal

More information

Does it matter which chemotherapy regimen you partner with the biologic agents?

Does it matter which chemotherapy regimen you partner with the biologic agents? Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

Media Release. Basel, 3 June 2012

Media Release. Basel, 3 June 2012 Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III

More information

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Bevacizumab is currently licensed for the following indication relevant for this NICE review: Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both

More information

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

45th ASCO Annual Meeting. Roche and Genentech Investor Event Part 1 Sunday, May 31, Orlando, Florida

45th ASCO Annual Meeting. Roche and Genentech Investor Event Part 1 Sunday, May 31, Orlando, Florida 45th ASCO Annual Meeting Roche and Genentech Investor Event Part 1 Sunday, May 31, 2009 - Orlando, Florida #1 Roche and Genentech This presentation contains certain forward-looking statements. These forward-looking

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity

Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12,

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12, Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq

More information

Colorectal Cancer Therapy and Associated Toxicity

Colorectal Cancer Therapy and Associated Toxicity Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated

More information

Merrimack Pharmaceuticals: A Refocused R&D Company January 2017

Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.

More information

FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019

FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019 FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Media Release. Basel, 21 July 2017

Media Release. Basel, 21 July 2017 Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential

More information

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and

More information

Media Release. Basel, 17 May 2018

Media Release. Basel, 17 May 2018 Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly

More information

A Fully Integrated Cancer Company.

A Fully Integrated Cancer Company. A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation

More information

For personal use only

For personal use only Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

Media Release. Basel, 7 May 2018

Media Release. Basel, 7 May 2018 Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche

More information

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu. R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking

More information

Review of Half Year 2010

Review of Half Year 2010 Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

Wells Fargo Healthcare Conference September 6, 2018

Wells Fargo Healthcare Conference September 6, 2018 Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are

More information

Citi Global Healthcare Conference

Citi Global Healthcare Conference Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

Media Release. Basel, 07 December 2017

Media Release. Basel, 07 December 2017 Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent

More information

Roche First quarter 2009 sales

Roche First quarter 2009 sales Roche First quarter sales April 16, This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects,

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

Media Release. Basel, 17 November 2012

Media Release. Basel, 17 November 2012 Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy

More information

Roche at a Glance An Introduction to our Company. February 2013

Roche at a Glance An Introduction to our Company. February 2013 Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active

More information

Roche delivers good sales growth in the first nine months of 2016

Roche delivers good sales growth in the first nine months of 2016 Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division

More information

Media Release. Basel, 20 March 2018

Media Release. Basel, 20 March 2018 Media Release Basel, 20 March 2018 Phase III IMpower131 study showed Roche s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the

More information

Under the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in

Under the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Basel, October 17, 2006

Basel, October 17, 2006 Roche Third quarter 2006 Basel, October 17, 2006 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Media Release. Basel, 18 February 2017

Media Release. Basel, 18 February 2017 Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma

More information

G1 Corporate Overview March 11, 2019

G1 Corporate Overview March 11, 2019 G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the

More information

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

Media Release. Basel, 6 th February 2018

Media Release. Basel, 6 th February 2018 Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain

More information

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014

More information

Arming the patient s immune system to fight cancer

Arming the patient s immune system to fight cancer Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information